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Interaction of the TNF homologues BLyS and APRIL with the TNF
receptor homologues BCMA and TACI
Scot A. Marsters*†, Minhong Yan*†, Robert M. Pitti*†, Philip E. Haas‡,
Vishva M. Dixit* and Avi Ashkenazi*
BLyS (also called TALL-1, THANK, or BAFF) [1–4] is a
member of the tumor necrosis factor (TNF) gene family
that stimulates proliferation and immunoglobulin
production by B cells. BLyS interacts with the TNF
receptor (TNFR) homologue TACI (transmembrane
activator and CAML-interactor) [5], and treatment of mice
with a TACI–Fc fusion protein abolishes germinal center
formation after antigenic challenge [6]. Here we report a
novel interaction between BLyS and another TNFR
homologue, BCMA (B cell maturation antigen) [7,8].
Further, the TNF homologue APRIL [9], a close relative
of BLyS, also bound to BCMA and TACI. BLyS or APRIL
activated nuclear factor-kB (NF-kB) through TACI and
BCMA, and each ligand stimulated immunoglobulin M
(IgM) production by peripheral blood B cells. These
results define a dual ligand–receptor system that may
play an important role in humoral immunity.
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Results and discussion
We have shown previously that BLyS binds to TACI and
stimulates NF-kB activity [6]. Unlike most members of
the TNFR gene family, which have 3 to 6 cysteine-rich
domains (CRDs) in the extracellular region, TACI has
two apparent CRDs [5]. One other TNFR homologue,
BCMA, appears to have only one CRD. Alignment of the
amino acid sequence of this CRD with the amino terminal
CRD of TACI revealed 11/33 identities (33%) (Figure 1a).
Given this similarity, we investigated whether BLyS
could interact with BCMA. We generated a soluble
BCMA–Fc fusion protein, and tested its ability to bind to
FLAG-epitope-tagged soluble BLyS in a co-immunopre-
cipitation assay (Figure 1b). FLAG–BLyS bound to
BCMA–Fc and to TACI–Fc , but not to Fc fusions of the
TNFR homologues Fas [10], or HVEM [11]. In contrast,
the TNF homologues FasL [12] and LIGHT [13] bound
as expected to Fas–Fc and HVEM–Fc, respectively, but
not to BCMA–Fc or TACI–Fc .
The closest structural homologue of BLyS (33% protein
sequence identity) is the TNF family member APRIL [9].
Given this similarity, we tested whether APRIL interacts
with BCMA or TACI (Figure 1b). Like BLyS, soluble
FLAG-tagged APRIL bound to BCMA–Fc and to
TACI–Fc . In contrast to a recent report [14], we did not
observe binding of FLAG–APRIL to Fas–Fc or HVEM–Fc
(Figure 1b). Immunoprecipitation of each ligand through
the FLAG tag followed by immunodetection of bound
receptor through the Fc tag revealed identical interactions
(data not shown).
Most TNF family members, including BLyS and APRIL,
are expressed as type 2 transmembrane proteins. To test
whether the transmembrane forms of these two ligands
recognize BCMA and TACI, we transfected COS7 cells
with expression vectors carrying each full-length ligand’s
cDNA, and stained the cells with receptor–Fc fusion pro-
teins. BCMA–Fc and TACI–Fc bound to cells transfected
Figure 1
(a) Comparison of the amino acid sequences of the amino-terminal
CRDs of BCMA and TACI. Identities are shown in bold. (b) Interaction
of BLyS and APRIL with BCMA and TACI. Purified BCMA–Fc,
TACI–Fc, Fas–Fc, or HVEM–Fc (1 mg/ml) was incubated with purified
FLAG–BLyS, FLAG–APRIL, FLAG–FasL, or FLAG–LIGHT (1 mg/ml)
as indicated for 1 h at 24°C. The reactions were subjected to
immunoprecipitation (IP) through the receptor–Fc fusion with protein-
A-agarose and analyzed by western blot (WB) with an anti-FLAG
antibody M2 (Sigma) to detect the bound ligands.
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with transmembrane BLyS or APRIL but not to cells
transfected with full-length TNF, whereas TNFR1–Fc
bound to cells transfected with TNF, but not to BLyS- or
APRIL-transfected cells (Figure 2a–i).
Unlike the majority of known TNFR family members
[15], but similar to TACI [5], BCMA does not contain a
typical amino-terminal signal sequence, suggesting that it
may be a type 3 rather than a type 1 transmembrane
protein. Previous work suggested that BCMA is located in
the Golgi compartment [16]. If BCMA and TACI are
expressed at the cell surface, then they should be recog-
nized in that location by BLyS and APRIL. To test this
notion, we transfected COS7 cells with expression vectors
encoding each native-sequence, full-length receptor, and
stained the cells with soluble alkaline-phosphatase (AP)
fusion proteins of each ligand (Figure 2j–o). Both
AP–BLyS and AP–APRIL bound to cells transfected with
BCMA or TACI but not to vector-transfected controls.
Thus, BCMA and TACI can localize to the cell surface,
where they can be identified by each ligand.
To assess the affinity of these interactions, we measured
the dosage dependence of ligand binding to each recep-
tor–Fc fusion protein (Figure 3). BLyS exhibited a slightly
higher affinity for TACI–Fc (KD = 160 ± 30 pM) as com-
pared to BCMA–Fc (KD = 260 ± 10 pM; Figure 3a).
APRIL, on the other hand, showed a somewhat higher
affinity for BCMA–Fc (KD = 500 ± 100 pM) than for
TACI–Fc (KD = 910 ± 200 pM; Figure 3b). Whereas FasL
and LIGHT showed a high level of binding, respectively,
to Fas–Fc and HVEM–Fc, BLyS showed no binding and
APRIL showed marginal binding (Figure 3). Thus, the
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Figure 2
Interaction of soluble receptors or ligands with cells transfected with
the corresponding binding partners. (a–i) COS7 cells were
transfected with expression plasmids encoding full-length (a–c) BLyS,
(d–f) APRIL, or (g–i) TNF [20], and 24 h later incubated with
BCMA–Fc, TACI–Fc, or TNFR1–Fc [21] as indicated for 1 h at 37°C.
The cells were washed, fixed, and the binding of Fc-fusion protein was
detected by biotinylated goat anti-human Fc antibody followed by
Cy3–streptavidin. (j–o) COS 7 cells were transfected with expression
plasmids encoding (j,k) native sequence full-length BCMA or
(l,m) TACI, or (n,o) with vector, and 24 h later incubated with
conditioned medium from 293 cells transfected with AP–BLyS or
AP–APRIL as indicated for 1 h at 37°C. The cells were washed, fixed,
and stained in situ for AP activity.
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Figure 3
Binding curves for ligand–receptor interactions. Fc-fusion proteins of
BCMA, TACI, Fas, or HVEM were immobilized on microtiter wells
coated with goat-anti-human Fc antibody, and incubated with varying
concentrations of purified FLAG-tagged BLyS (a), APRIL (b), FasL or
LIGHT (a,b) as indicated for 1 h at 24°C. The binding was determined
with biotinylated anti-FLAG M2 antibody followed by colorimetric
substrate conversion with horseradish peroxidase-conjugated
streptavidin. The plots are from one of three to four representative
experiments, from which mean ± SE of the apparent dissociation
constant (KD) were calculated (see text).
1001010.10.010.001
1001010.10.010.001
A
4
9
0 
nm
A
4
9
0 
nm
(b)
(a)
FasL/Fas
BLyS/BCMA
BLyS/TACI
BLyS/Fas
LIGHT/HVEM
BLyS/HVEM
FasL/Fas
APRIL/BCMA
APRIL/TACI
APRIL/Fas
LIGHT/HVEM
 Current Biology   
APRIL/HVEM
1.5
1.0
0.5
0
1.5
1.0
0.5
0
Ligand (µg/ml)
Ligand (µg/ml)
binding of BLyS or APRIL to BCMA or TACI occurs at
apparently physiological concentrations.
The signaling mechanisms of BCMA have not been char-
acterized. Therefore, we investigated whether BCMA
activates NF-kB in response to BLyS (Figure 4a,b). In
addition, we tested APRIL’s ability to stimulate NF-kB
through BCMA or TACI. Treatment of 293 cells trans-
fected with expression vectors encoding native sequence,
full-length BCMA or TACI with purified soluble FLAG-
tagged BLyS or APRIL induced marked NF-kB activation
relative to controls, as measured by a reporter-gene assay
(Figure 4a). Next, we examined whether co-transfection
of 293 cells with expression plasmids encoding each full-
length ligand and receptor combination leads to NF-kB
stimulation (Figure 4b). BLyS and APRIL induced signif-
icant NF-kB activation through BCMA and TACI. Thus,
both BLyS and APRIL can stimulate NF-kB through
either BCMA or TACI. TACI has been reported to acti-
vate the T cell transcription factor NF-AT [5]. Because
BCMA and TACI activated NF-kB despite the lack of
clear sequence homology in their cytoplasmic region, it is
formally possible that BCMA can activate NF-AT as well. 
BLyS is implicated in B-cell activation and it stimulates
immunoglobulin production by B cells [1–4,17]. We inves-
tigated whether APRIL modulates B cells as well by
testing B cell IgM production in cultures of peripheral
blood leukocytes (Figure 4c). Both BLyS and APRIL
induced a marked enhancement of IgM production, similar
to interleukin-4 (IL-4). TACI–Fc and BCMA–Fc inhibited
the effect of BLyS and APRIL but not of IL-4. Combina-
tion of BLyS and APRIL did not result in further stimula-
tion (data not shown), consistent with the notion that the
two ligands use the same receptors to modulate B cells.
Our results demonstrate that BLyS is not the sole ligand
of TACI and BCMA; rather, the closest relative of BLyS
in the TNF gene family, APRIL, interacts with these
same receptors. APRIL has been reported to stimulate the
growth of various tumor cell lines [9]; however, its physio-
logical role is not fully understood. Whether TACI,
BCMA, or some other receptor(s) mediate APRIL-
induced proliferation is yet to be investigated. 
In previous work, we identified TACI as a B-cell receptor
for BLyS by expression cloning [6]. Treatment of mice
with a TACI–Fc fusion protein after antigenic challenge
diminished IgM and IgG production and abolished
splenic germinal center formation. These data suggested
that the interactions of BLyS and TACI are crucial for
humoral immunity. During review of this manuscript,
Gross et al. [18] reported that TACI and BCMA are
receptors for BLyS and showed that treatment with
TACI–Fc ameliorated disease and improved survival in
mouse models of systemic lupus erythematosus (SLE), a
B-cell-mediated autoimmune disease. Taken together,
these findings suggest that TACI–Fc exerts its therapeu-
tic effect on mouse SLE by perturbing the generation of
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Figure 4
Activation of NF-kB and of IgM production by BLyS and APRIL.
(a) Human 293 cells were transfected with the indicated amounts of
expression plasmids encoding native sequence full-length BCMA or
TACI along with 0.25 mg of ELAM-luciferase reporter gene plasmid,
and 25 ng pRL-TK. After 4 h, purified soluble FLAG-tagged BLyS or
APRIL was added at the indicated concentration for 20 h, and reporter
gene activity determined with the dual-luciferase reporter assay system
(Promega). (b) Human 293 cells were co-transfected with the
indicated amounts of expression plasmids for each ligand-receptor
combination and NF-kB activity was determined as above. (c) Human
peripheral blood leukocytes were incubated for 72 h with PBS, or IL-4
(100 ng/ml), or FLAG–BLyS or FLAG–APRIL (1 mg/ml), alone, or in
combination with 20 mg/ml TACI–Fc, BCMA–Fc, or a human IgG1
control. Cell supernatants were analyzed for IgM levels by ELISA
(Bethyl Laboratories). The data are means ± SEM of four experiments.
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autoantibodies. Although these effects of TACI–Fc were
previously ascribed to inhibition of BLyS [6,18], this
study, which uncovers APRIL as a second ligand for
TACI, suggests that APRIL inhibition also may con-
tribute to the effects of TACI–Fc on immunization and
SLE. In addition, it is likely that TACI–Fc blocks the
interactions of BLyS and APRIL not only with cellular
TACI, but also with BCMA, which is expressed in lym-
phoid organs and B lymphocytes [19]. Thus, BLyS and
APRIL and their receptors TACI and BCMA may act in
concert to regulate B-cell function. Further studies, par-
ticularly gene knockout experiments, should help define
more fully the individual contribution of each member of
this newly defined ligand–receptor system to humoral
immunity in health and disease.
Materials and methods
Fc fusion proteins (immunoadhesins) were constructed using amino
acids 5–51 of human BCMA [7,8], 2–166 of human TACI [5], 1–170 of
Fas [10], or 1–199 of HVEM [11], and expressed in Chinese hamster
ovary (CHO) cells using a heterologous signal sequence (prepro-trypsin
amino acids 1–17) for BCMA and TACI, or the endogenous signal
sequence for Fas and HVEM. FLAG-tagged ligands were constructed in
pCMV-1 Flag (Sigma) using amino acids 124–285 of human BLyS [1],
105–250 of human APRIL [9], 103–251 of human FasL, and 82–240
of human LIGHT [13]. Ligands were expressed in CHO cells and puri-
fied by affinity chromatography on anti-Flag M2-agarose (Sigma).
AP fusion proteins were constructed by inserting the human AP coding
sequence derived from pAPtag-5 (Genehunter Corp.) into each pCMV-
1 FLAG–ligand vector between the Flag tag and the ligand sequences.
The total amount of transfected DNA in co-transfection experiments
was kept constant at 1 mg by supplementation with empty vector. 
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